Dr. Samia Rourou is a researcher at the Institut Pasteur de Tunis (Tunisia) in the field of biotechnology (vaccines and recombinant proteins). She holds a Biology Engineering Master's and a Ph.D. degree in biological sciences (biotechnology).
In October 1999, Dr. Rourou joined the Institut Pasteur de Tunis (IPT) as a biotechnology engineer (viral vaccines development unit). In September 2010, she defended her Ph.D. thesis in biological sciences entitled "Culture of Vero cells and production of rabies virus under animal component free conditions: process development & proteomics study". In October 2011, she was appointed as an assistant biologist at IPT.
Dr. Rourou is involved in biopharmaceutical development programs within IPT. Since 2020, she has led the biotechnology development group. She has greatly contributed to various vaccine development processes (e.g., rabies vaccines for veterinary and human use based on BHK-21 and Vero cells culture in a stirred bioreactor, measles’s vaccine, sheep pox vaccine, Newcastle vaccine) and recombinant proteins (e.g., HGG and a biosimilar monoclonal antibody on CHO cells, S-RBD of SARS-Cov2 using BEV).
In January 2016, she was selected by WHO/TDR for a Career Development Fellowship (CRDF) in the glycoconjugate vaccines preclinical laboratory at GSK, Siena, Italy.
She then received a re-entry grant to organize “BioPharmaTun”, the First Tunisian International Symposium on Biopharmaceuticals: from Bench to Bedside (November 2017).
Dr. Samia Rourou is a researcher at the Institut Pasteur de Tunis (Tunisia) in the field of biotechnology (vaccines and recombinant proteins). She holds a Biology Engineering Master's and a Ph.D. degree in biological sciences (biotechnology).
In October 1999, Dr. Rourou joined the Institut Pasteur de Tunis (IPT) as a biotechnology engineer (viral vaccines development unit). In September 2010, she defended her Ph.D. thesis in biological sciences entitled "Culture of Vero cells and production of rabies virus under animal component free conditions: process development & proteomics study". In October 2011, she was appointed as an assistant biologist at IPT.
Dr. Rourou is involved in biopharmaceutical development programs within IPT. Since 2020, she has led the biotechnology development group. She has greatly contributed to various vaccine development processes (e.g., rabies vaccines for veterinary and human use based on BHK-21 and Vero cells culture in a stirred bioreactor, measles’s vaccine, sheep pox vaccine, Newcastle vaccine) and recombinant proteins (e.g., HGG and a biosimilar monoclonal antibody on CHO cells, S-RBD of SARS-Cov2 using BEV).
In January 2016, she was selected by WHO/TDR for a Career Development Fellowship (CRDF) in the glycoconjugate vaccines preclinical laboratory at GSK, Siena, Italy.
She then received a re-entry grant to organize “BioPharmaTun”, the First Tunisian International Symposium on Biopharmaceuticals: from Bench to Bedside (November 2017).